Sinopharm: manufacturing segments, subsidiaries, equipment and FUZKK utilities
A group-level case study for a utility recommendation system: public business segment → representative manufacturing process and equipment → quality data → specific FUZKK packages and utilities.
How the recommendation constructor works
1. Company segment
Vaccines, plasma, chemical pharma, TCM, devices, engineering, logistics or R&D.
2. Process and equipment
Identify the representative process chain and systems that generate laboratory or manufacturing data.
3. Quality requirement
Separate lifecycle/QMS/software requirements, pharmacopoeial instrumental QC and product/API-specific checks.
4. Utility set
Select specific utilities, not only a package name; the result can form the basis of a pilot scope.
Company navigation
Public segment map
| Segment | Public specialisation | Primary FUZKK layer |
|---|---|---|
| CNBG and the biopharma segment: vaccines, antibodies, diagnostics and bioproducts | Sinopharm's public profile describes more than 20 biopharma manufacturing enterprises centred on CNBG and six areas: human vaccines, blood products, medical aesthetics, animal health, antibody drugs and medical diagnostics. | |
| Beijing Tiantan Biological and plasma-derived products | Beijing Tiantan Biological Products belongs to the CNBG structure. For plasma manufacturing, the key areas are plasma-pool traceability, viral safety, fractionation, protein purification and release review for albumin, immunoglobulins and coagulation factors. | |
| Shanghai Shyndec: chemical medicines, APIs, antibiotic intermediates and finished dosage forms | Shyndec's official profile states that it has 20 production bases across 12 provinces and municipalities and held 1,451 drug approvals at the end of 2024. Its public product scope includes antibiotic intermediates/APIs, chemical medicines and finished dosage forms. | |
| Sinopharm Zhijun Pingshan: high-end chemical pharma, modern TCM and environmental manufacturing control | Sinopharm Zhijun Pingshan is publicly described as a key Shyndec enterprise integrating development and manufacturing of high-end chemical pharmaceuticals and modern TCM formulations, together with VOC-treatment, energy-saving and environmental-improvement projects. | |
| China TCM Holdings: raw materials, primary processing, extracts, formula granules and proprietary medicines | Sinopharm describes a complete TCM chain from cultivation and research to production and sales, with particular scale in formula granules, primary processing and proprietary Chinese medicines. | |
| Taiji Group, Southwest Pharmaceutical and Tongjunge: TCM plus modern medicines | Taiji Group combines TCM development with modern medicines. Public examples within the group include Southwest Pharmaceutical as a production base for important medicines and Tongjunge as a manufacturer of proprietary Chinese medicines. | |
| Sinopharm Medical Equipment: imaging, IVD, minimally invasive instruments, consumables and wearables | Sinopharm's public medical-equipment profile includes medical imaging, minimally invasive surgical instruments, in-vitro diagnostics, medical consumables, protective supplies and intelligent wearable devices. | |
| Sino Pharmengin: pharmaceutical engineering, GMP verification, control and information systems | Sinopharm reports more than 6,000 pharmaceutical-engineering designs and technical services, together with consulting, design, project management, EPC, GMP-verification consulting and specialised control/information, fluid, energy and environmental engineering. | |
| Sinopharm Holding and Sinopharm International: distribution, logistics, projects and cold chain | Sinopharm publicly describes Asia's largest pharmaceutical logistics network serving more than 700,000 end customers. Sinopharm International works with more than 100 suppliers and international pharmaceutical and medical projects. | |
| China State Institute of Pharmaceutical Industry: R&D, evaluation and transfer to manufacturing | CSIPI is publicly described as Sinopharm's institute for research, development and evaluation of new pharmaceuticals and technologies, pharmaceutical production and sales. |
CNBG and the biopharma segment: vaccines, antibodies, diagnostics and bioproducts
Sinopharm's public profile describes more than 20 biopharma manufacturing enterprises centred on CNBG and six areas: human vaccines, blood products, medical aesthetics, animal health, antibody drugs and medical diagnostics.
Vaccines and viral safety
Biologic characterisation
Beijing Tiantan Biological and plasma-derived products
Beijing Tiantan Biological Products belongs to the CNBG structure. For plasma manufacturing, the key areas are plasma-pool traceability, viral safety, fractionation, protein purification and release review for albumin, immunoglobulins and coagulation factors.
Plasma-derived products
Sterility and laboratory control
Shanghai Shyndec: chemical medicines, APIs, antibiotic intermediates and finished dosage forms
Shyndec's official profile states that it has 20 production bases across 12 provinces and municipalities and held 1,451 drug approvals at the end of 2024. Its public product scope includes antibiotic intermediates/APIs, chemical medicines and finished dosage forms.
Antibiotic intermediates and fermentation
APIs and finished dosage forms
Sinopharm Zhijun Pingshan: high-end chemical pharma, modern TCM and environmental manufacturing control
Sinopharm Zhijun Pingshan is publicly described as a key Shyndec enterprise integrating development and manufacturing of high-end chemical pharmaceuticals and modern TCM formulations, together with VOC-treatment, energy-saving and environmental-improvement projects.
Chemical QC
TCM and botanical QC
QMS, change and process control
China TCM Holdings: raw materials, primary processing, extracts, formula granules and proprietary medicines
Sinopharm describes a complete TCM chain from cultivation and research to production and sales, with particular scale in formula granules, primary processing and proprietary Chinese medicines.
Fingerprint and markers
Contaminants
Taiji Group, Southwest Pharmaceutical and Tongjunge: TCM plus modern medicines
Taiji Group combines TCM development with modern medicines. Public examples within the group include Southwest Pharmaceutical as a production base for important medicines and Tongjunge as a manufacturer of proprietary Chinese medicines.
TCM manufacturing
Finished dosage forms
Sinopharm Medical Equipment: imaging, IVD, minimally invasive instruments, consumables and wearables
Sinopharm's public medical-equipment profile includes medical imaging, minimally invasive surgical instruments, in-vitro diagnostics, medical consumables, protective supplies and intelligent wearable devices.
Design, risk and QMS
Software and cybersecurity
Electrical, usability, sterile and UDI
Sino Pharmengin: pharmaceutical engineering, GMP verification, control and information systems
Sinopharm reports more than 6,000 pharmaceutical-engineering designs and technical services, together with consulting, design, project management, EPC, GMP-verification consulting and specialised control/information, fluid, energy and environmental engineering.
Qualification, calibration and validation
Control software and data integrity
Sinopharm Holding and Sinopharm International: distribution, logistics, projects and cold chain
Sinopharm publicly describes Asia's largest pharmaceutical logistics network serving more than 700,000 end customers. Sinopharm International works with more than 100 suppliers and international pharmaceutical and medical projects.
Cold chain and stability
Supplier and incoming controls
China State Institute of Pharmaceutical Industry: R&D, evaluation and transfer to manufacturing
CSIPI is publicly described as Sinopharm's institute for research, development and evaluation of new pharmaceuticals and technologies, pharmaceutical production and sales.
Analytical methods
Technology transfer and change
Group-level pilot scope
For Sinopharm, a practical start is three reproducible pilots rather than all segments at once; each pilot demonstrates a separate layer of a future recommendation system.
Vaccines / biologics
Residual DNA/HCP, sterility, endotoxin, adjuvant, aggregation, cold chain and release readiness.
Shyndec / APIs and dosage forms
HPLC assay/impurities, GC residual solvents, KF water, ICP elemental impurities, antibiotic intermediates, dissolution and content uniformity.
Medical equipment and engineering
QMS, risk, software lifecycle, cybersecurity, calibration, process validation, cleanroom and data-integrity evidence.
Public sources
- Sinopharm — group profile and business sectors
- Sinopharm — Bio-pharm
- Sinopharm — Chemical Pharmaceuticals
- Sinopharm — Traditional Chinese Medicine
- Sinopharm — Medical Equipment
- Sinopharm — Engineering Technology
- Shanghai Shyndec Pharmaceutical
- China Traditional Chinese Medicine Holdings
- Chongqing Taiji Industry Group
- Sinopharm Holding
- Sinopharm International — international projects
- China State Institute of Pharmaceutical Industry